Menu Search
Equities

Zhejiang Orient Gene Biotech Co Ltd

688298:SHH

Zhejiang Orient Gene Biotech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)32.19
  • Today's Change-1.14 / -3.42%
  • Shares traded2.69m
  • 1 Year change-26.22%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Zhejiang Orient Gene Biotech Co Ltd's revenues fell -90.65% from 8.77bn to 820.16m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 2.07bn to a loss of 397.58m.
Gross margin39.26%
Net profit margin-75.73%
Operating margin-75.33%
Return on assets-7.18%
Return on equity-8.01%
Return on investment-8.27%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Zhejiang Orient Gene Biotech Co Ltd fell by 3.63bn. Cash Flow from Financing totalled 49.54m or 6.04% of revenues. In addition the company used 1.65bn for operations while cash used for investing totalled 2.12bn.
Cash flow per share--
Price/Cash flow per share--
Book value per share34.13
Tangible book value per share30.32
More ▼

Balance sheet in CNYView more

Zhejiang Orient Gene Biotech Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.44% of the market capitalization can be attributed to its 2.93bn and debt could be paid in full if management chose.
Current ratio4.09
Quick ratio3.71
Total debt/total equity0.0824
Total debt/total capital0.0744
More ▼

Growth rates in CNY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -100.00% and -119.20%, respectively.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		44.17
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.